As a principal scientist, you will work on a projects that builds on the success of Adstiladrin®, which itself has changed the paradigm for treatment of NMIBC by using a non-replicating adenoviral delivery system to target gene expression to the tumor site. You will help drive our efforts to develop the next generation of gene delivery systems by selecting relevant transgenes for delivery, developing constructs to meet current regulatory guidelines, and demonstrating efficacy in relevant in vitro and in vivo models.
You are entrepreneurial, innovative, and understand the drug discovery process. You have a background in immune-oncology and experience of gene delivery in a pharma industry setting would be an advantage. With your strong collaboration and communication skills, you can gather insight from colleagues across the organization and will become an internal subject matter expert.
Denmark On-site Pre-clinical Research and Development Ferring Pharmaceuticals